Relmada Therapeutics, Inc.
RLMD
$7.49
$0.040.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -57.39M | -56.17M | -67.81M | -75.71M | -79.98M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.55M | 18.26M | 22.19M | 25.88M | 29.81M |
| Change in Net Operating Assets | -3.95M | -2.08M | -4.31M | -6.95M | -1.58M |
| Cash from Operations | -45.79M | -39.99M | -49.92M | -56.79M | -51.76M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -48.14M | 40.14M | 49.53M | 56.86M | 51.56M |
| Cash from Investing | -48.14M | 40.14M | 49.53M | 56.86M | 51.56M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 93.64M | 0.00 | 0.00 | 0.00 | 246.70K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -73.00K | -245.50K | -335.10K | -262.10K | -287.10K |
| Cash from Financing | 93.56M | -245.50K | -335.10K | -262.10K | -40.40K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -360.50K | -99.40K | -733.00K | -185.40K | -234.70K |